🔎 Trials Near Me

Почетна › Рак плућа › Тексас

Kliničke studije za Рак плућа u državi Тексас

101 studija za Рак плућа traži učesnike na lokacijama u državi Тексас.

Gradovi u državi Тексас

Zvanični tekst studije (na engleskom)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Oncology Consultants PA, Houston
  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 13. 11. 2026. · NCT05920356

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas
  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07063745

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

  • Texas Oncology - DFW ( Site 8003), Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06780098

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

  • The University of Texas M. D. Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06909201

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • University of Texas MD Anderson Cancer Center, Houston
  • Local Institution - 0173, San Antonio
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07100080

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • The University of Texas, MD Anderson Cancer Center - Woodlands, Conroe
  • Renovatio Clinical - El Paso, El Paso
  • The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
  • и још 10
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06758401

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Hendrick Medical Center, Abilene
  • Houston Methodist San Jacinto Hospital, Baytown
  • Parkland Memorial Hospital, Dallas
  • и још 7
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

  • Audie Murphy VA Medical Center, San Antonio
  • Brooke Army Medical Center, San Antonio
Тражи се учесник
Узраст од 50 до 80 · Оба пола · Ажурирано 12. 11. 2026. · NCT07168993

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • и још 2
Тражи се учесникФаза 3
Узраст 70 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06096844

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

  • The University of Texas MD Anderson Cancer Center, Houston
  • NEXT Oncology, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07458347

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  • GSK Investigational Site, Fort Worth
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07099898

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • The University of Texas Health Science Center at Tyler, Tyler
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • The University of Texas Southwestern Medical Center at Dallas, Dallas
  • Renovatio Clinical - El Paso, El Paso
  • JPS Health Network, Fort Worth
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Houston Methodist San Jacinto Hospital, Baytown
  • Houston Methodist Cypress Hospital, Cypress
  • Parkland Memorial Hospital, Dallas
  • и још 10
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT04181060

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The University of Texas - MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • The University of Texas MD Anderson Cancer Center (site 127), Houston
Тражи се учесникФаза 1/2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT03556228

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

  • Mary Crowley Cancer Research, Dallas
  • MD Anderson, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07857616

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07492680

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Texas Oncology, Austin
  • William Beaumont Army Medical Center, Fort Bliss
  • Houston Methodist Hospital, Houston
  • и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

  • M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06060613

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

  • START San Antonio, LLC, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07903415

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • Texas Oncology, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07185997

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  • University of Texas, MD Anderson Cancer Center, Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07499674

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

  • Research Site, Houston
  • Research Site #2, San Antonio
  • Research Site, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06835569

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT02984761

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • University of Texas MD Anderson Cancer Center, Houston
  • NEXT Dallas, Irving
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06922591

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Texas Medical Branch, Galveston
  • The University of Texas MD Anderson Cancer Center, Houston
  • Baylor Scott & White Health, Temple
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07154290

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Houston
Тражи се учесникФаза 2
Узраст од 18 до 95 · Оба пола · Ажурирано 21. 10. 2026. · NCT05061550

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT06810544

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics, LLC, San Antonio
  • UT Health San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06244771

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • The University of Texas MD Anderson Cancer Center, Houston
  • NEXT Oncology Dallas, Irving
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06162221

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Dallas
  • Avenzo Therapeutics Recruiting Site, Houston
  • Avenzo Therapeutics Recruiting Site, San Antonio
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 16. 10. 2026. · NCT07038343

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • The University of Texas MD Anderson Cancer Center, Houston
  • Texas Oncology Cancer Center, Sugar Land
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06712355

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • MD Anderson Cancer Center, Houston
  • START San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Start - Dfw, Fort Worth
  • Oncology Consultants, Houston
  • START - San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • The Don and Sybil Harrington Cancer Center, Amarillo
Тражи се учесникФаза 2
18 Minutes · Оба пола · Ажурирано 9. 10. 2026. · NCT06031688

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.